Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute - Seite 2

Dr Patrick McHugh, Community Liaison for Mātai, confirms that the trial will centre on training local clinicians, rongoa (traditional Māori medicine) specialists and marae community members as kaitieki (guides) in psychedelic assisted therapy. Additionally, it will involve integrating the associated kawa and tikanga (cultural practices and protocols) into the therapeutic experience, making this the first trial of its kind in Aotearoa.

“We recognise that, alongside many First Nations peoples, we have a relationship with native flora and fauna as a source of healing and reconnection to our respective indigenous cultural practices,” says Jody Toroa, trustee of Rangiwaho Marae. "Optimi medicines provide the closest natural fungi to the marae’s local, indigenous species, which for Rangiwaho Marae and the Tū Wairua collective, is key to the integrity of the project. Synthetic products, by comparison, are not conducive to our reclaiming of cultural knowledge and customary practice,” says Jody.

In New Zealand, any registered prescriber can apply through the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) for permission to administer an unapproved medicine.

As the only fully equipped Canadian psychedelics pharmaceutical manufacturer, Optimi is well-positioned to meet large-scale demand for GMP psilocybin and MDMA drug products through its 10,000 sq ft cultivation and formulation facility.

For media inquiries, please contact Michael Kydd:

[e-mail]
902.880.6121

For investor inquiries, please contact:
[e-mail]

www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. IS a leading Health Canada licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as GMP-grade natural psilocybin and MDMA for clinical research purposes and patient access programs, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe and compliant GMP drug candidates throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.